Day One Biopharmaceuticals DAWN

HealthcareMarket cap $3B0 connections

Day One Biopharmaceuticals develops precision pediatric cancer drugs. Its tovorafenib received FDA approval for pediatric low-grade glioma - the most common brain tumor in children - making it the first oral chemotherapy for this indication. Pediatric oncology is an area of significant unmet need with limited competition.

Explore Day One Biopharmaceuticals on the interactive map Relationship timeline Find a path to another company

We haven't documented any relationships for this company yet.

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Day One Biopharmaceuticals's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=DAWN" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Day One Biopharmaceuticals on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.